A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-016-3069-8
Published Online: 2016-06-14
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cao, Junning
Zhang, Jian
Peng, Wei
Chen, Zhiyu
Fan, Songhua
Su, Weiguo
Li, Ke
Li, Jin
License valid from 2016-06-14